Process validation is an extension of biologics development processes.
When it comes to outsourcing process validation of biologics, Abel Hastings, director of process sciences at FUJIFILM Diosynth Biotechnologies, says that the relationship between a contract development and manufacturing organization (CDMO) and sponsor is key in ensuring successful process validation. “Customers that are open about their strategy, their data (good and bad), and their own strengths and weaknesses are most successful.”
BioPharm International spoke with Hastings about the specific challenges that arise in the process validation of biologics.
Read this article in BioPharm International's Outsourcing Resources 2018 eBook.
View other articles in BioPharm International'sOutsourcing Resources 2018 eBook.
BioPharm Internationalâ¨
eBook: Outsourcing Resources 2018
â¨Vol. 31â¨
March 2018â¨
Pages: 22–23
When referring to this article, please cite it as S. Haigney, "Process Validation in Biologics Development," BioPharm International Outsourcing Resources eBook (March 2018).
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.